ADDITIONAL PUBLICATIONS DISCUSSED DURING THE PROGRAM

No abstract available. Berges O et al. Concurrent radiation therapy and bortezomib in myeloma patients. Radiother Oncol 2008;[Epub ahead of print].

Abstract 8009. Coiffier B et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. Proc ASCO 2007.

Abstract. Fenk R et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007;48(12):2345-51.

Abstract. Friedberg JW et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26(2):204-10.

Abstract 8004. Hochster HS et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB Intergroup E1496 trial. Proc ASCO 2007.

Abstract 8062. Kahl BS et al. A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma. Proc ASCO 2007.

Abstract 8033. Kaminski MS et al. I131-tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 years. Proc ASCO 2007.

Abstract 8011. Morrison VA et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. Proc ASCO 2007.

No abstract available. Zhan F et al. High-risk myeloma: A gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008;111(2):968-9.